Ipsen reports positive data from pancreatic ductal adenocarcinoma trial

Ipsen has announced positive data from the Phase III NAPOLI 3 trial of an investigational regimen of Onivyde (irinotecan liposome injection) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), who were not treated earlier.